Market Place
Sourcing Support
Gilead declines another Arcus option after Phase 3 TIGIT fail
20 Apr 2026 //
ENDPOINTS
MSF Decries Gilead`s Revised Yeztugo Access Plan
15 Apr 2026 //
FIERCE PHARMA
PEPFAR, Global Fund expand access to Gilead’s lenacapavir
14 Apr 2026 //
BUSINESSWIRE
Global Fund Expands Commitment To Improve Access To HIV Drug
14 Apr 2026 //
REUTERS
Kymera Announces Gilead’ Option Exercise to License KT-200
10 Apr 2026 //
ENDPOINTS NEWS
Cartography`s Strategic First Option Target Exercise with Gilead
09 Apr 2026 //
PHARMIWEB
Gilead Exercises Kymera`s KT-200 Option
09 Apr 2026 //
GLOBENEWSWIRE
Tempus Announces Collab with Gilead to Advance Oncology R&D
09 Apr 2026 //
BUSINESSWIRE
Gilead Pays Kymera $45M For Preclinical Protein Degrader
09 Apr 2026 //
FIERCE BIOTECH
Gilead to buy Germany`s Tubulis for up to $5 billion
07 Apr 2026 //
PRESS RELEASE
Gilead Lays Off Employees At California Headquarters
03 Apr 2026 //
BIOSPACE
Gilead Cancels HIV Trial As Clinical Hold Remains Intact
01 Apr 2026 //
FIERCE BIOTECH
Gilead Extends Tender Offer to Acquire Arcellx
01 Apr 2026 //
BUSINESSWIRE
Galapagos, Gilead Partner On 1st-In-Class T Cell Engager Program
31 Mar 2026 //
GLOBENEWSWIRE
BMS, Novartis, Gilead, Iovance Dinged In CBER Untitled Letters
30 Mar 2026 //
FIERCE PHARMA
Gilead Sciences to Acquire Ouro Medicines
26 Mar 2026 //
BUSINESSWIRE
Gilead Inks Manta Pact To Dive Deeper Into Cancer Patient Aid
24 Mar 2026 //
FIERCE PHARMA
Gilead Chief Gets 20% Pay Bump, Still Falls Short Of $30M Club
24 Mar 2026 //
BIOSPACE
Gilead Sciences to Acquire Ouro Medicines for Autoimmune Diseases
23 Mar 2026 //
BUSINESSWIRE
Gilead Boosts CEO O`Day`S 2025 Compensation By 20% To $28.4M
23 Mar 2026 //
FIERCE PHARMA
Gilead Turns Down Assembly`s Ph. 1-Stage HBV Antiviral
21 Mar 2026 //
FIERCE BIOTECH
Gilead Turns Down Assembly`s Ph. 1-Stage HBV Antiviral
20 Mar 2026 //
FIERCE BIOTECH
Manufacturing Is Key To Gilead`s Yeztugo Prep Rollout: Exec
13 Mar 2026 //
FIERCE PHARMA
Gilead Foundation Awards $12M for HIV Prevention Programs
02 Mar 2026 //
PHARMIWEB
One2PrEP`: Gilead`s 1st Yeztugo ad highlights biannual dosing
02 Mar 2026 //
FIERCE PHARMA
Gilead, Merck Clear Path for Daily HIV Pills with Late-Stage Data
26 Feb 2026 //
BIOSPACE
Gilead experimental HIV treatment shows Low discontinuation rate
26 Feb 2026 //
REUTERS
Gilead`s Bictegravir/Lenacapavir Sustains HIV Virologic Control
25 Feb 2026 //
BUSINESSWIRE
Gilead Sciences To Present At Upcoming Investor Conferences
23 Feb 2026 //
BUSINESSWIRE
Gilead To Unveil HIV Treatment And Prevention Data At CROI 2026
17 Feb 2026 //
BUSINESSWIRE
Gilead in licensing deal with Chinese biotech for cancer therapy
16 Feb 2026 //
FIERCE BIOTECH
Gilead Proactive in Deals Despite M&A`s Low Urgency Priority
11 Feb 2026 //
BIOSPACE
‘Pieces are coming together’ amid Gilead`s Yeztugo launch
11 Feb 2026 //
FIERCE PHARMA
Gilead Sciences Unveils 2025 Full-Year Financial Results
10 Feb 2026 //
BUSINESSWIRE
Gilead Announces 3.8% Dividend Increase for Q1 2026
10 Feb 2026 //
BUSINESSWIRE
The Biggest Potential Drug Launches Of 2026
06 Feb 2026 //
FIERCE PHARMA
FDA Approves Label Update For Kite`s Yescarta® In Cns Lymphoma
06 Feb 2026 //
BUSINESSWIRE
Gilead`s Yescarta Approved For Expanded Patient Use
06 Feb 2026 //
FIERCE PHARMA
Gilead Sciences Releases Q4, FY 2025 Results on Feb. 6
27 Jan 2026 //
BUSINESSWIRE
4D Path Joins Phase II Trial to Advance Predictive Diagnostics
22 Jan 2026 //
GLOBENEWSWIRE
NEJM: Ph 3 ASCENT-04/KEYNOTE-D19 Trodelvy+Keytruda Supports SoC
21 Jan 2026 //
BUSINESSWIRE
JPM26: Gilead Captures Mood With Yezugo, HIV Data
14 Jan 2026 //
BIOSPACE
JPM26: Gilead Eyes New Deals From A `Position Of Strength`
14 Jan 2026 //
FIERCE BIOTECH
Xilio Therapeutics Highlights Upcoming Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Study Finds HIV Can Evolve To Resist Lenacapavir—At A Cost
07 Jan 2026 //
FIERCE BIOTECH
RAAP: Alternative Funding Programs Put Rare Patients In Jeopardy
07 Jan 2026 //
PR NEWSWIRE
Onconano, Gilead Partner To Apply ON-BOARD Tech To Drug
06 Jan 2026 //
BUSINESSWIRE
Abbvie, Gilead Gift Themselves Clinical-Stage Cancer Drugs
02 Jan 2026 //
FIERCE BIOTECH
Gilead Licenses Assembly Bio`s Herpes Drugs After Positive Phase
24 Dec 2025 //
INDPHARMAPOST
Gilead Sciences Acquires RP-3467, Pol-ATPase Inhibitor RP 3467
24 Dec 2025 //
BUSINESSWIRE
Gilead pays $35M to license pair of HSV assets from Assembly Bio
24 Dec 2025 //
BUSINESSWIRE
Gilead Sciences To Present At Upcoming Investor Conference
22 Dec 2025 //
BUSINESSWIRE
Gilead, U.S. Government Collaborate To Reduce Medicine Costs
19 Dec 2025 //
BUSINESSWIRE
Gilead Sciences Names Keeley Wettan as EVP, General Counsel
18 Dec 2025 //
BUSINESSWIRE
Gilead`s HIV Single-Tablet Regimen Meets Phase 3 Trial Goal
15 Dec 2025 //
BUSINESSWIRE
Arcus Updates Phase 3 STAR-221 Study, Focuses R&D On Casdatifan
12 Dec 2025 //
PHARMIWEB
Therapy Eases Side Effects for 75% of Black Breast Cancer
10 Dec 2025 //
BUSINESSWIRE
Gilead Foundation Grants $3M For Metastatic Breast Cancer Support
09 Dec 2025 //
BUSINESSWIRE
Gilead, J&J Lead CAR-T In Multiple Myeloma; Fulcrum Soars
08 Dec 2025 //
BIOSPACE
Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
